Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: A randomized, double-blinded, controlled multicentre clinical trial

Developmental Medicine and Child Neurology

Volumn 53, Issue 3, 2011, Pages 239-244

  Kim, Keewon ^a   Shin, Hyung Ik ^b   Kwon, Bum Sun ^c   Kim, Sang Jun ^a   Jung, Il Young ^a   Bang, Moon Suk ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Dongguk University Ilsan Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; NEURONOX; UNCLASSIFIED DRUG;

ARTICLE; CEREBRAL PALSY; CHILD; DOUBLE BLIND PROCEDURE; DRUG COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FACIAL NERVE PARALYSIS; FEMALE; GAIT DISORDER; GROSS MOTOR FUNCTION MEASURE; HEMIPLEGIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANGE OF MOTION; SCHOOL CHILD; SPASTIC EQUINUS GAIT; SPASTICITY; TREATMENT RESPONSE;

BOTULINUM TOXINS, TYPE A; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EQUINUS DEFORMITY; FEMALE; GAIT DISORDERS, NEUROLOGIC; HUMANS; INJECTIONS; MALE; MOTOR SKILLS; NEUROMUSCULAR AGENTS; RANGE OF MOTION, ARTICULAR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79551532049     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2010.03830.x     Document Type: Article

References (26)

1. Koman LA, Mooney JF III, Smith B, Goodman A, Mulvaney T. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop 1993; 13: 489-95.
2. Koman LA, Mooney JF III, Smith BP, Goodman A, Mulvaney T. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 1994; 14: 299-303.
3. Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994; 36: 386-96.
4. Moore AP, Ade-Hall RA, Smith CT, et al. Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy. Neurology 2008; 71: 122-8.
5. Lukban MB, Rosales RL, Dressler D. Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence. J Neural Transm 2009; 116: 319-31.
6. Kanovsky P, Bares M, Severa S, Richardson A. Long-term efficacy and tolerability of 4-monthly versus yearly botulinum toxin type A treatment for lower-limb spasticity in children with cerebral palsy. Dev Med Child Neurol 2009; 51: 436-45.
7. Stone AV, Ma J, Whitlock PW, et al. Effects of BOTOX and Neuronox on muscle force generation in mice. J Orthop Res 2007; 25: 1658-64.
8. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med 2010; 8: 18.
9. Kang BS, Bang MS, Jung SH. Effects of botulinum toxin A therapy with electrical stimulation on spastic calf muscles in children with cerebral palsy. Am J Phys Med Rehabil 2007; 86: 901-6.
10. Bakheit AMO. Botulinum Toxin Treatment of Muscle Spasticity. Milton Keynes: AuthorHouse, 2007.
11. Matilde Sanchez M, Chen X. Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat. Stat Med 2006; 25: 1169-81.
12. Koman LA, Brashear A, Rosenfeld S, et al. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 2001; 108: 1062-71.
13. Russell D, Rosenbaum P, Avery L, Lane M. Gross Motor Function Measure (GMFM-66 & GMFM-88) User's Manual. London: Mac Keith Press, 2002.
14. Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord 1998; 13: 150-4.
15. Ubhi T, Bhakta BB, Ives HL, Allgar V, Roussounis SH. Randomized double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 2000; 83: 481-7.
16. Koman LA, Mooney JF III, Smith BP, Walker F, Leon JM. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 2000; 20: 108-15.
17. Lewis JA. Statistical principles for clinical trials (ICH E9): an introductory note on an international guideline. Stat Med 1999; 18: 1903-42.
18. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990; 300: 230-5.
19. Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol 2006; 13(Suppl. 1): 2-10.
20. Abbruzzese G, Berardelli A. Neurophysiological effects of botulinum toxin type A. Neurotox Res 2006; 9: 109-14.
21. Camargo CH, Teive HA, Zonta M, et al. Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy. Arq Neuropsiquiatr 2009; 67: 62-8.
22. Baker R, Jasinski M, Maciag-Tymecka I, et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 2002; 44: 666-75.
23. Bakheit AM, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001; 8: 559-65.
24. Wissel J, Heinen F, Schenkel A, et al. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "low-dose" treatment. Neuropediatrics 1999; 30: 120-4.
25. Mall V, Heinen F, Siebel A, et al. Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study. Dev Med Child Neurol 2006; 48: 10-3.
26. Bakheit AM, Severa S, Cosgrove A, et al. Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity. Dev Med Child Neurol 2001; 43: 234-8.